IPO filing research

BirchBioMed Inc.

Pharmaceutical Preparations

ipo amended Nasdaq S-1

BirchBioMed Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-08-12. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Shares · Exchange Nasdaq

BirchBioMed Inc. is a pre-revenue clinical-stage biopharmaceutical company with a limited operating history and escalating losses. The company focuses on developing product candidates across its NHP/Cosmetics and Pharmaceutical Rx platforms, with FS2 topical cream approved in Canada as an NHP but no products currently on the market. Key challenges include securing FDA approval in the U.S., reliance on partnerships for commercialization, and significant financial and operational risks. The company anticipates continued losses and requires additional capital to advance clinical programs and achieve profitability.

2026-08-12 · 0001493152-26-037435

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-07-01 · 0001493152-26-031579

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-05-01 · 0001493152-26-020930

DRS/A amended